Zobrazeno 1 - 10
of 269
pro vyhledávání: '"Arnold G Vulto"'
Autor:
Daniel Aletaha, Katerina Chatzidionysiou, Alfons A den Broeder, Paco M J Welsing, Rieke Alten, Bart van den Bemt, Denis Mulleman, James Galloway, John Isaac, P Verschueren, Arnold G Vulto, Céleste J T van der Togt, Lise Verhoef
Publikováno v:
RMD Open, Vol 9, Iss 1 (2023)
Objectives To develop evidence-based points to consider for cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases, specifically rheumatoid arthri
Externí odkaz:
https://doaj.org/article/f64b1aa1443047fba5492f01d5e31545
Autor:
Evelien Moorkens, Arnold G Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E Martikainen, Gisbert W Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon, Steven Simoens
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0190147 (2017)
Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.The aim of this article is to provide an overview of different initiatives and policies tha
Externí odkaz:
https://doaj.org/article/48cd055a3a8d489ebf5008a91ccd2ff9
Autor:
Erhard van der Vries, Koert J Stittelaar, Geert van Amerongen, Edwin J B Veldhuis Kroeze, Leon de Waal, Pieter L A Fraaij, Roland J Meesters, Theo M Luider, Bart van der Nagel, Birgit Koch, Arnold G Vulto, Martin Schutten, Albert D M E Osterhaus
Publikováno v:
PLoS Pathogens, Vol 9, Iss 5, p e1003343 (2013)
Immunocompromised individuals tend to suffer from influenza longer with more serious complications than otherwise healthy patients. Little is known about the impact of prolonged infection and the efficacy of antiviral therapy in these patients. Among
Externí odkaz:
https://doaj.org/article/bc27865fd6ff43239c72447f6d265e1d
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: By improving the affordability and accessibility of biologicals, biosimilar competition provides important benefits to healthcare systems and patients. In Belgium, biosimilar uptake and competition is limited compared to other European ma
Externí odkaz:
https://doaj.org/article/d0642ba99427483988e89756f00aa7c8
Autor:
Qiushi, Liang, Fabio, Catalano, Eva C, Vlaar, Joon M, Pijnenburg, Merel, Stok, Yvette, van Helsdingen, Arnold G, Vulto, Ans T, van der Ploeg, Niek P, van Til, W W M Pim, Pijnappel
Publikováno v:
Molecular Therapy-Methods and Clinical Development, 27, 109-130. Cell Press
Pompe disease is caused by deficiency of acid α-glucosidase (GAA), resulting in glycogen accumulation in various tissues, including cardiac and skeletal muscles and the central nervous system (CNS). Enzyme replacement therapy (ERT) improves cardiac,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1addc5c7da444efdddb989fc4cff2cc
https://doi.org/10.1016/j.omtm.2022.09.010
https://doi.org/10.1016/j.omtm.2022.09.010
Publikováno v:
American Journal of Health-System Pharmacy, 79(22), 2001-2011. American Society of Health-Systems Pharmacy
Purpose With the growing availability of biosimilars on the global market, clinicians and pharmacists have multiple off-patent biological products to choose from. Besides the competitiveness of the product’s price, other criteria should be consider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e479a5ad5b985baa5b3e7ae219fc5dfe
https://doi.org/10.1093/ajhp/zxac235
https://doi.org/10.1093/ajhp/zxac235
Autor:
Arnold G. Vulto
Publikováno v:
HemaSphere, Vol 3, Iss 6, p e322 (2019)
Externí odkaz:
https://doaj.org/article/6aa743fad644498bb0d70b43003acbe1
Publikováno v:
BioDrugs, 36(2), 217-229. Adis
BACKGROUND: To encourage the rational prescribing of biologics, payers across Europe have experimented with the implementation of benefit-sharing programs. Benefit-sharing programs are incentive programs that promote the use of 'best-value' off-paten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd38d262b302af4bebccbd6e0f93f5cf
https://doi.org/10.1007/s40259-022-00523-z
https://doi.org/10.1007/s40259-022-00523-z
Autor:
Henk C. Hoogsteden, Joost P.J.J. Hegmans, Rudi W. Hendriks, Arnold G. Vulto, Bronno van der Holt, Eric Braakman, Cynthia Waasdorp, Ferry A.L.M. Eskens, André Kunert, Niken M. Mahaweni, Cor H. van der Leest, Koen Bezemer, Margaretha E.H. Kaijen-Lambers, Robin Cornelissen, Pauline L. de Goeje, Joachim G.J.V. Aerts
Purpose: Mesothelioma has been regarded as a nonimmunogenic tumor, which is also shown by the low response rates to treatments targeting the PD-1/PD-L1 axis. Previously, we demonstrated that autologous tumor lysate–pulsed dendritic cell (DC) immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c01604ce053715c2dca9b66ef0a9ab
https://doi.org/10.1158/1078-0432.c.6525983.v1
https://doi.org/10.1158/1078-0432.c.6525983.v1
Autor:
Henk C. Hoogsteden, Joost P.J.J. Hegmans, Rudi W. Hendriks, Arnold G. Vulto, Bronno van der Holt, Eric Braakman, Cynthia Waasdorp, Ferry A.L.M. Eskens, André Kunert, Niken M. Mahaweni, Cor H. van der Leest, Koen Bezemer, Margaretha E.H. Kaijen-Lambers, Robin Cornelissen, Pauline L. de Goeje, Joachim G.J.V. Aerts
Supplementary Material and Methods: Preparation of allogeneic tumor lysate Figure S1: CD8 T-cells from DC immunotherapy treated mice show tumor cell killing capacity Figure S2: Progression free survival of patients in the first-in-human clinical stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f97b6c8e3225f046d755e41fbb18e34
https://doi.org/10.1158/1078-0432.22465283.v1
https://doi.org/10.1158/1078-0432.22465283.v1